Summing up 15 years of somatostatin analog therapy in neuroendocrine tumors: Future outlook

Annals of Oncology

Volumn 10, Issue SUPPL. 2, 1999, Pages

  Eriksson, B ^a   Oberg K ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Apoptosis; Lanreotide treatment; Neuroendocrine gastrointestinal tumors; Octreotide; Somatostatin analogs

Indexed keywords

5 HYDROXYINDOLEACETIC ACID; ANGIOPEPTIN; OCTREOTIDE; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR; VAPREOTIDE;

ABDOMINAL CRAMP; ACUTE PANCREATITIS; APOPTOSIS; BRADYCARDIA; CARCINOID; CONFERENCE PAPER; DIARRHEA; DRUG MECHANISM; DRUG RECEPTOR BINDING; EXOCYTOSIS; FLATULENCE; GASTRINOMA; GASTROINTESTINAL TUMOR; GLUCAGONOMA; HORMONE SYNTHESIS; HUMAN; HYPOCALCEMIA; INSULINOMA; NAUSEA; NEUROENDOCRINE TUMOR; PRIORITY JOURNAL; QUALITY OF LIFE; SLOW RELEASE FORMULATION; SOMATOSTATINOMA; TACHYPHYLAXIS; TRANSIENT ISCHEMIC ATTACK; TUMOR GROWTH; VIPOMA;

EID: 0033058738     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/10.suppl_2.S31     Document Type: Conference Paper

References (63)

1. Norheim I, Öberg K, Theodorson-Norheim E et al. Malignant carcinoid tumors. An analysis of 103 patients with regard to tumor localization, hormone production, and survival. Ann Surg 1987; 206: 115-25.
2. Eriksson B, Arnberg H, Lindgren PG et al. Neuroendocrine pancreatic tumors: Clinical presentation, biochemical and histopathological findings in 84 patients. J Intern Med 1990; 228: 103-13.
3. Öberg K, Norheim I, Lundqvist G, Wide L. Cytotoxic treatment in patients with malignant carcinoid tumors: Response to streptozocin - alone or in combination with 5-FU. Acta Oncol 1987; 26: 429-32.
4. Moertel CG, Lefkoponto M, Lipsity M. Streptozocin-doxorubicin, streptozocin fluorouracil, or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med 1992; 326: 519-23.
5. Oberg K, Norheim I, Lind E et al. Treatment of malignant carcinoid tumors with human leukocyte interferon. Long-term results. Cancer Treat Rep 1986; 70: 1297-304.
6. Eriksson B, Öberg K. An update of the medical treatment of malignant endocrine pancreatic tumors. Acta Oncol 1993; 32: 203-8.
7. Carrasco CH, Chuang V, Wallace S. Apudoma metastatic to the liver: Treatment by hepatic artery embolization. Radiology 1983; 149: 79-83.
8. Carrasco CH, Charnsangavej C, Ajani J et al. The carcinoid syndrome: Palliation by hepatic artery embolization. AJR 1986; 147: 149-54.
9. Reubi JC, Kvols LK, Waser B et al. Detection of somatostatin receptors in surgical and percutaneous needle biopsy samples and islet cell carcinomas. Cancer Res 1990; 50: 5969-77.
10. 3]-octreotide. The Rotterdam experience with more than 1000 patients. Eur J Nucl Med 1993; 20: 716-31.
11. 1]-Octreotide scintigraphy in patients with carcinoid tumors: The predictive value for somatostatin analog treatment. Eur J Endocrinol 1994; 131: 577-81.
12. Lamberts SW, van der Lely AJ, De Herder WW, Hofland LJ. Octreotide. N Engl J Med 1996; 334: 246-54.
13. Yamada Y, Post SR, Wang et al. Cloning and characterization of a family of human and mouse somatostatin receptors expressed in brain, gastrointestinal tract and kidney. Proc Natl Acad Sci 1992; 89: 251-5.
14. Yamada Y, Reisine T, Law SF et al. Somatostatin receptors, an expanding gene family: Cloning and functional characterization of human SSTR 3, a protein coupled to adenylylcyclase. Mol Endocrinol 1992; 6: 2136-42.
15. Yamada Y, Kagimoto S, Kubota A et al. Cloning, functional expression and pharmacological characterization of a fourth (hSSTR) and fifth (hSSTR) human somatostatin receptor subtype. Biochem Biophys Res Comm 1993; 195: 844-52.
16. O'Carrol AM, Lolait SJ, König M, Mahan LC. Molecular cloning and expresssion of a pituitary somatostatin receptor with preferential affinity for somatostatin-28. Mol Pharmacol 1992; 42: 939-46.
17. Fröhlich JC, Bloomgarden ZT, Oates JA et al. The carcinoid flush: Provocation by pentagastrin and inhibition by somatostatin. N Engl J Med 1978; 299: 1055-7.
18. Thulin L, Samnegård H, Tyden G et al. Efficacy of somatostatin in a patient with carcinoid syndrome. Lancet 1978; 2: 43.
19. Bauer W; Briner U, Doepfner W et al. SMS 201-995: A very potent and selective octapeptide analogue of somatostatin with prolonged action. Life Sci 1982; 31: 1133-40.
20. Kvols LK, Marsh HM, Moertel CG. Rapid reversal of carcinoid crisis with a somatostatin analogue. N Engl J Med 1985; 313: 1229-30.
21. Öberg K, Norheim I, Lundqvist G, Wide L. Treatment of the carcinoid syndrome with SMS 201-995, a somatostatin analogue. Scand J Gastroenterol 1986; 119: 191-2.
22. Kvols LK, Moertel CG, O'Connell MJ et al. Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue. N Engl J Med 1986; 315: 663-6.
23. Gorden P, Comi RJ, Maton PN, Go VLW. Somatostatin and somatostatin analogue (SMS 201-995) in treatment of hormone-secreting tumors of the pituitary and gastrointestinal tract and non-neoplastic diseases of the gut. Ann Intern Med 1989; 110: 35-50.
24. Wynick D, Anderson JV, Williams SJ, Bloom SR. Resistance of metastatic pancreatic endocrine tumours after long-term treatment with the somatostatin analogue octreotide (SMS 201-995). Clin Endocrinol 1989; 30: 385-8.
25. Maton PN, Gardner JD, Jensen RT. Use of long-acting somatostatin analogue SMS 201-995 in patients with pancreatic islet cell tumors. Dig Dis Sci 1989; 34: 285-91.
26. Scarpignato C. Somatostatin analogues in the management of endocrine tumors of the pancreas. In Mignon M, Jensen RT (eds): Endocrine Tumors of the Pancreas. Basel: Karger 1995; 385-414.
27. Lamberts SWJ, Krenning EP, Reubi JC. The role of somatostatin and its analogs in the diagnosis and treatment of tumors. Endocrinol Rev 1991; 12: 450-82.
28. Tiensuu Janson E, Gobl A, Kälkner KM, Öberg K. Comparison between the efficacy of somatostatin receptor scintigraphy and that of in situ hybridization for somatostatin receptor subtype 2 messenger RNA to predict therapeutic outcome in carcinoid patients. Cancer Res 1996; 56: 2561-5.
29. Ruszniewski P, Ramdani A, Cadiot G et al. Long-term treatment with octreotide in patients with the Zollinger-Ellison syndrome. Eur J Clin Invest 1993; 23: 296-301.
30. Wood SM, Kraenzlin ME, Adrian TE, Bloom SR. Treatment of patients with pancreatic endocrine tumors using a new long-acting somatostatin analogue: Symptomatic and peptide response. Gut 1985; 26: 438-44.
31. Jockenhovel S, Lederbogen S, Olbricht T et al. The long-acting somatostatin analogue octreotide alleviates symptoms by reducing post-translational conversion of preproglucagon to glucagon in a patient with malignant glucagonoma, but does not prevent tumor growth. Clin Invest 1994; 72: 127-33.
32. Angeletti S, Corleto VD, Schillachi O et al. Use of the somatostatin analogue octreotide to localise and manage somatostatin-producing tumours. Gut 1998; 42: 792-4.
33. Harris A, Redfern JS. Octreotide treatment of carcinoid syndrome: Analysis of published dose-titration data. Aliment Pharmacol Ther 1995; 9: 387-94.
34. Saltz L, Trochanowski B, Buckley M et al. Octreotide as an antineoplastic agent in the treatment of functional and non-functional neuroendocrine tumors. Cancer 1993; 72: 244-8.
35. Arnold R, Trautmann ME, Creutzfeldt W et al. Somatostatin analogue and inhibition of tumor growth in metastatic endocrine gastroenteropancreatic tumors. Gut 1996; 38: 430-8.
36. Kvols LK, Buck M, Moertel CG et al. Treatment of metastatic islet cell carcinoma with a somatostatin analogue (SMS 201-995). Ann Intern Med 1987; 107: 162-8.
37. Vinik A, Moattari AR. Use of somatostatin analog in management of carcinoid syndrome. Dig Dis Sci 1989; 34: 14-27.
38. Kraenzlin ME, Ch'ng JLC, Wood SM et al. Long-term treatment of a VIP-oma with somatostatin analogue resulting in remission of symptoms and possible shrinkage of metastases. Gastroenterology 1985; 88: 185-7.
39. Bartholomeo M, Bajetta E, Buzzoni R et al. Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors. A study by the Italian Trials in Medical Oncology Group. Cancer 1996; 77: 402-8.
40. Kvols LK, Moertel CG, Schutt AJ, Rubin J. Treatment of the malignant carcinoid syndrome with a long acting somatostatin analogue (SMS 201-995): Preliminary evidence that more is not better. Proc Am Soc Clin Oncol 1987; 6: 95.
41. Eriksson B, Öberg K, Andersson T et al. Treatment of malignant endocrine pancreatic tumors with a new long-acting somatostatin analogue, SMS 201-995. Scand J Gastroenterol 1988; 23: 508-12.
42. Öberg K, Norheim I, Theodorsson E. Treatment of malignant midgut carcinoid tumours with a long-acting somatostatin analogue octreotide. Acta Oncol 1991; 30: 503-7.
43. Janson ET, Öberg K. Long-term management of the carcinoid syndrome: Treatment with octreotide alone and in combination with α-interferon. Acta Oncol 1993; 32: 225-9.
44. Taylor JE, Bogden AE, Moreau JP, Coy DH. In vitro inhibition of human small-cell carcinoma (NCL-H69) growth by somatostatin analogue. Biochem Biophys Res Commun 1988; 153: 81-6.
45. Weckbecker G, Liu R, Tolcsvai L, Bruns C. Antiproliferative effects of the somatostatin analogue octreotide (SMS 201-995) on ZR-75-1 human breast cancer cells in vivo and in vitro. Cancer Res 1992; 52: 4973-8.
46. Buscail L, Esteve JP, Saint-Laurent N et al. Inhibition of cell proliferation by the somatostatin analogue RC-160 is mediated by somatostatin receptor subtypes SSTR2 and SSTR5 through different mechanisms. Proc Natl Acad Sci 1995; 92: 1580-4.
47. Trendle MC, Moertel CG, Kvols LK. Incidence and morbidity of cholelithiasis in patients receiving chronic octreotide for metastatic carcinoid and malignant islet cell tumors. Cancer 1997; 79: 830-4.
48. Lambert SWJ, van der Lely AJ, de Herder WW, Hofland LJ. Somatostatin analogs: Future directions. Metabolism 1996; 45: 104-6.
49. Eriksson B, Renstrup J, Imam H, Öberg K. High-dose treatment with lanreotide of patients with advanced neuroendocrine gastrointestinal tumors: Clinical and biological effects. Ann Oncol 1997; 8: 1041-4.
50. Imam H, Eriksson B, Lukinius A et al. Induction of apoptosis in neuroendocrine tumors of the digestive system during treatment with somatostatin analogs. Acta Oncol 1997; 36: 607-14.
51. Sharma K, Patel XC, Srikant CB. Subtype-selective induction of wild-type p53 and apoptosis, but not cell cycle arrest, by human somatostatin receptor 3. Mol Endocrinol 1996; 10: 1688-96.
52. 11C-dopamine. J Nucl Med 1996; 36: 32-7.
53. Anthony L, Johnson D, Hande K et al. Somatostatin analogue phase I trials in neuroendocrine neoplasms. Acta Oncol 1993; 32: 217-23.
54. Faiss S, Wiedenmann B. Dose-dependent and antiproliferative effects of somatostatin. J Endocrinol Invest 1997; 20: 68-70.
55. Harris A, Kokoris S, Ezzat S. Continuous versus intermittent subcutaneous infusion of octreotide in the treatment of acromegaly. J Clin Pharmacol 1995; 35: 59-71.
56. Eriksson B, Janson ET, Bax NDS et al. The use of new somatostatin analogues, lanreotide and octastatin, in neuroendocrine gastrointestinal tumors. Digestion 1996; 57: 77-80.
57. Hofland LJ, Koetsveld, Waaijers M et al. Relative potencies of the somatostatin analogs octreotide, BIM-23014, and RC-160 on the inhibition of hormone release by cultures human endocrine tumor cells and normal rat anterior pituitary cells. Endocrinol 1994; 134: 301-6.
58. Lancranjan I, Bruns C, Grass P et al. Sandostatin-LAR: Pharmacokinetics, pharmacodynamics, efficacy, and tolerability in acromegalic patients. Metabolism 1995; 44: 18-26.
59. Ruszniewski P, Ducreux M, Chayvialle JA et al. Treatment of the carcinoid syndrome with the long-acting somatostatin analogue lanreotide: A prospective study in 39 patients. Gut 1996; 39: 279-83.
60. Scherübl H, Wiedenmann B, Riecken EO et al. Treatment of the carcinoid syndrome with a depot formulation of the somatostatin analogue lanreotide. Eur J Cancer 1994; 6: 1590-1.
61. Wymenga ANM, Eriksson B, Salmela PI et al. Efficacy and safety of lanreotide prolonged release in patients with gastrointestinal neuroendocrine tumors with hormone related symptoms. J Clin Oncol, in press.
62. Janson ET, Ahlström H, Andersson T, Öberg K. Octreotide and interferon-α: A new combination for the treatment of malignant carcinoid tumors. Eur J Cancer 1992; 28A: 1647-50.
63. Shimon I, Taylor J, Weiss MH et al. Somatostatin receptor (SSTR) subtype-selective analogues differentially suppress in vitro growth hormone and prolactin in human pituitary adenomas. Novel potential therapy for functional pituitary tumors. J Clin Invest 1997; 100: 2386-92.